On October 26, 2026, medical oncology consortiums affirmed the clinical utility of Tibsovo® (Ivosidenib 250 mg tablets) by Servier for IDH1-mutated acute myeloid leukemia (AML) and advanced cholangiocarcinoma.

By competitively inhibiting mutant isocitrate dehydrogenase-1 (IDH1), Tibsovo reverses oncometabolite-driven epigenetic dysregulation across both hematologic malignancies and solid gastrointestinal tumors.

Through Critical Kare Pharma, verified original manufacturer cartons of Tibsovo Ivosidenib 250mg Tablets are supplied to hospital oncology departments globally.

The ClarIDHy & AGILE Clinical Milestones

• ClarIDHy Phase 3 (Cholangiocarcinoma): Demonstrated statistically significant improvement in progression-free survival and overall survival in advanced IDH1-mutated biliary cancer.
• AGILE Phase 3 (Frontline AML): Ivosidenib plus azacitidine tripled median overall survival (24.0 months vs. 7.9 months) in older newly diagnosed AML patients.
• Dosing: Standard dosage is 500 mg orally once daily taken with or without food. Avoid high-fat meals.

Global Named-Patient Sourcing via Critical Kare Pharma

Managed under official import exemptions across North America, Europe, Asia-Pacific, and Latin America.